Press Release Nokia upgrades Orange Jordan's broadband network gateway to enhance connectivity across the Kingdom #MWC25 State-of-the-art Nokia 7750 SR BNG deployed to elevate broadband services and user experience in Jordan. Strategic upgrade to 76 sites across the Kingdom reduces operational costs and boosts network efficiency.

This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. After a busy early February, the pace of dividend increases slowed down as we moved into the latter half of the month, with only 10 companies boosting their annual dividend. But included in that number are several significant companies, including the widely followed Coca-Cola, Walmart and Home Depot.

Danaher Corp. has faced market punishment recently, but maintains strong margins and impressive FCF despite a tough year, indicating resilience and potential for future growth. The company's strategic capital allocation, including share buybacks and acquisitions, suggests management is positioning for long-term value creation, despite short-term pessimism. Danaher's bioprocessing segment shows consistent growth, and the upcoming patent cliff is expected to provide significant tailwinds, boosting demand for their life science equipment.

U.S. rig counts rise for a third week, raising concerns about oversupply. Will this cap oil and natural gas prices, or is there still room for a rally?

Provident Financial Services is a U.S. regional bank focused on mortgage lending in New Jersey, Pennsylvania, and New York. The bank's Q4 2024 results reflected the final costs of the merger with Lakeland Bancorp. Looking ahead to 2025, the bank expects no additional merger costs and a stable net interest margin.

I rate Pfizer a sell for the next 18–24 months. I expect continued headwinds from Medicare Part D redesign and patent expirations for Eliquis and Prevnar-13 in 2026. Medicare changes will cut $1 billion from 2025 revenue, with PFE now responsible for 20% of catastrophic drug costs. Danuglipron could be Pfizer's turnaround catalyst if late stage trials succeed in 2025. I expect its potential launch in late 2026 or early 2027 to boost investor sentiment.

The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently, did not like the bottom-line results nor the uninspiring guidance for 2025. Still, West should not be overlooked, and there may be opportunities if the share price continues to rebound after a market overreaction.

Occidental Petroleum has disappointed shareholders with acquisitions reducing shareholder returns. The bonds with about 7% YTM do look attractive. We elucidate our rationale.

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome.

PayPal's strategic shift under Alex Chriss focuses on profitable growth by enhancing core strengths, increasing user engagement, and accelerating innovation velocity. Q4 earnings showed mixed results with revenue and EPS beats, but higher OpEx led to market disappointment; while strategic initiatives aim for long-term outperformance. Key initiatives include enhancing checkout experiences, expanding debit and credit offerings, and boosting SMB merchant onboarding to drive user habituation and profitable growth.

Christopher Richter, CLSA's senior analyst for Japanese autos, discusses the the impact of U.S. tariffs on Japanese automakers.

ProFrac Holding remains undervalued with a bright long-term outlook driven by efficiency gains and fleet upgrades. Record efficiency gains and significant investments in high-tech, environmentally friendly fleets are expected to drive future shareholder value despite depressed free cash flow. Demand for power generation driven by AI and industrial electrification presents a strong growth opportunity.

Asian markets diverge: Hang Seng rebounds on AI strength, Nikkei climbs on GDP data, but ASX 200 drops as RBA rate cut uncertainty lingers.

WICHITA, Kan.--(BUSINESS WIRE)--Textron Aviation announced an Australia expansion with construction of a larger, modernized service facility at Essendon Fields Airport.

Upland Software has shown bullish technical indicators, including price action above the 30-week EMA, strong momentum, and institutional buying volume. Despite a history of declining stock prices, UPLD's recent performance and management's positive outlook suggest potential for growth, aiming for a $10 target. The company's fundamentals reveal a slightly negative current ratio but improving free cash flow and strategic plans for debt reduction and sales growth.

Walmart reports their fiscal Q4 '25 financial results before the opening bell on February 20, 2025. Consensus expectations are for $0.53 in EPS, $180.2 billion in revenue and $6.8 billion in operating income, for expected y-o-y growth of -12%, +4% and -6% respectively. Walmart's “price-to-sales” has traded below 1x for 89 straight quarters, and it's only been the last 2 quarters that price-to-sales has been over 1x - at exactly 1x last quarter - and if revenue consensus is met, will trade 1.22x on Thursday morning, February 20, 2025. Its P/E multiple expanded from 25X in fiscal Q1 '24 to …

Home Depot is a mature company with limited growth prospects, and its current stock price is overpriced relative to its intrinsic value. The company's operating margins have resumed their pre-pandemic decline, and recent acquisitions raise concerns about management's capital discipline. Despite strong historical performance, insider trading activity suggests insiders believe HD shares have been overpriced for some time.

ADT's renewed focus on the residential market, debt reduction, and exiting unprofitable ventures signal a more streamlined and profitable future. Strategic partnerships with Google and State Farm enhance growth, reduce customer acquisition costs, and improve service offerings. ADT's valuation is attractive with a forward P/E-multiple of 9.3x, supported by strong earnings growth and potential for higher multiples.

NEW YORK, NY / ACCESS Newswire / February 16, 2025 / If you suffered a loss on your Integral Ad Science Holding Corp. (NASDAQ:IAS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/integral-ad-science-lawsuit-submission-form?prid=129952&wire=1 or contact Joseph E. Levi, Esq.

Exxon Mobil reported strong Q4'24 earnings and free cash flow, driven by production growth from the Pioneer Natural Resources acquisition, despite lower petroleum prices. I maintain a strong buy rating for Exxon Mobil due to its robust free cash flow, reasonable valuation, and growth potential in the Permian Basin. Exxon Mobil generated $8.0B in free cash flow in Q4'24, showing flat FCF growth due to higher production volumes offsetting pricing weakness.